MAURICIO DENER CORDEIRO
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Tumor mutational burden (TMB) and BCG responsiveness in high-risk non-muscle invasive bladder cancer (NMIBC).(2019) BASTOS, Diogo Assed; LIMA, Mariana; MATTEDI, Romulo Loss; SANTOS, Filipe Ferreira dos; BUZATTO, Vanessa; BARREIRO, Rodrigo; RIBEIRO-FILHO, Leopoldo; CORDEIRO, Mauricio; AMANO, Mariane; SOUZA, Jussara Michaloski; BETTONI, Fabiana; GALANTE, Pedro Alexandre Favoretto; DZIK, Carlos; NAHAS, William Carlos; CAMARGO, Anamaria Aranha
- A rare case of tumor-to-tumor metastasis: Prostate cancer to chromophobe renal cell carcinoma(2019) CAVALCANTE, Alexandre; CORDEIRO, Mauricio D.; SIERRA, Pablo S.; JR, Jose Pontes; V, Emanuel Albuquerque; BARBOSA, Paulyana F.; MATTEDI, Romulo L.; FARAJ, Sheila F.; COELHO, Rafael F.; NAHAS, William C.
conferenceObject CORRELATION BETWEEN MICRORNAS AND MRNA EXPRESSION PROFILES WITH THE PROGNOSIS OF CLINICALLY LOCALIZED PENILE CANCER(2019) MURTA, Claudio; PONTES JR., Jose; FURUYA, Tatiane; UNO, Miyuki; CARRASCO, Alexis; COELHO, Rafael; GUGLIELMETTI, Giuliano; CORDEIRO, Mauricio; FARAJ, Sheila; LEITE, Katia; SICHERO, Laura; VILLA, Luisa; SROUGI, Miguel; CHAMMAS, Roger; NAHAS, William- Tumor contact length used as a biomarker to predict extracapsular extension, lymph node involvement, and biochemical recurrence.(2019) VIANA, Publio; RODRIGUES, Thiana; MOTA, Davi Alves Martins; GUGLIELMETTI, Giuliano; BASTOS, Diogo Assed; FAZOLI, Arnaldo; NAHAS, William Carlos; COELHO, Rafael; CORDEIRO, Mauricio; HORVAT, Natally
- Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center(2019) AMARAL, Alexandre Franco; OLIVEIRA, Martina Rodrigues de; DIAS, Olivia Meira; ARIMURA, Fabio Eiji; FREITAS, Carolina Salim Goncalves; ACENCIO, Milena Marques Pagliarelli; ALVARENGA, Vanessa Adelia de; KAIRALLA, Ronaldo Adib; CARVALHO, Carlos Roberto Ribeiro; BALDI, Bruno Guedes; SCLEROSIS, Tuberous; BALBO, Bruno Eduardo Pedroso; WATANABE, Elieser Hitoshi; SAMORANO, Luciana Paula; ONUCHIC, Luiz Fernando; RIVITTI-MACHADO, Maria Cecilia da Matta; MANREZA, Maria Luiza Giraldes de; CORDEIRO, Mauricio Dener; TAKAHASHI, Patricia; OLIVEIRA, Zilda Najjar Prado deIntroductionSerum vascular endothelial growth factor-D (VEGF-D) is a lymphangiogenic growth factor that is considered a valuable tool in the diagnosis of lymphangioleiomyomatosis (LAM). Previous studies have reported a wide variability in VEGF-D serum levels in LAM patients and it seems to be associated with pulmonary impairment and lymphatic involvement.MethodsWe conducted a cross-sectional study from 2009 to 2017 that evaluated VEGF-D serum levels in a cohort of LAM patients who were never treated with mTOR inhibitors and compared them to healthy age-matched volunteers. Clinical and functional parameters were assessed and correlated with their respective serum VEGF-D levels.ResultsOne hundred and four patients were included in the analysis. Serum VEGF-D levels were higher in LAM patients compared to healthy controls: 796 (404-1588) versus 162 (117-232)pg/mL, respectively (p<0.001). Patients with tuberous sclerosis complex-LAM, TSC-LAM (20%), had higher levels of VEGF-D when compared to patients with sporadic LAM (80%) [1005 (641-2732) vs. 772 (370-1383), p=0.05]. Serum VEGF-D levels were weakly correlated with DLCO (r=-0.26, p=0.001) and lymphatic involvement was more frequent in those with serum VEGF-D levels equal or above 800pg/mL (35% vs. 13%, p=0.02).ConclusionsIn LAM, serum VEGF-D is weakly associated with lung function impairment and strongly associated with lymphatic involvement. VEGF-D is validated for use in Brazilian patients with LAM whose characteristics must be accounted for when evaluating their serum VEGF-D levels.
- Multiparametric magnetic resonance imaging (mpMRl) and PSA density for the prediction of reclassification among patients under active surveillance.(2019) VIANA, Publio; HORVAT, Natally; PESSOA, Rodrigo Rodrigues; HORVAT, Joao; PARK, Rubens; GUGLIELMETTI, Giuliano; BASTOS, Diogo Assed; CORDEIRO, Mauricio; COELHO, Rafael; VARGAS, Hebert Alberto; NAHAS, William Carlos